A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-08
Target enrollment:
Participant gender:
Summary
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index \[BMI\] 30 kg/m2), or overweight (BMI 27 kg/m2) and at least one weight-related comorbidity